Evidence for the recognition of non-nucleotide antagonists within the transmembrane, domains of the human P2Y1 receptor

被引:23
作者
Guo, DP
von Kügelgen, I
Moro, S
Kim, YC
Jacobson, KA
机构
[1] NIDDK, Mol Recognit Sect, Lab Bioorgan Chem, NIH, Bethesda, MD 20892 USA
[2] Univ Bonn, Dept Pharmacol, D-5300 Bonn, Germany
[3] Univ Padua, Dept Pharmaceut Sci, Padua, Italy
[4] Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju, South Korea
关键词
antagonists; G protein-coupled receptors; mutagenesis; phospholipase C; nucleotides;
D O I
10.1002/ddr.10145
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Site-directed mutagenesis was used to search for amino acid residues of the human P2Y(1) receptor involved in the binding of the P2 receptor antagonists pyridoxal-5'-phosphate-6-azophenyl-2,4-disulfonate(PPADS), its analogue 6-(2'-chloro-phenylazo)-pyridoxal-alpha(5)-phosphate (MRS 2210), the suramin analogue 8-8'-[carbonylbis(imino-3,1-phenylene)] bis(1,3,5-naphthalene-trisulfonate) (NF023), and Reactive blue 2. Receptors containing single amino acid replacements at positions in transmembrane helical domains (TMs) 3, 5, 6, and 7 critical for the activation of the receptor by nucleotide agonists were expressed in COS-7 (African green monkey kidney) cells. Inositol phosphate accumulation was induced by 2-methylthioadenosine 5'-diphosphate (2-MeSADP). In wild type human P2Y(1) receptors, PPADS (10 to 60 muM), MRS 2210 (10 muM), NF023 (100 muM), and Reactive blue 2 (10 muM) shifted the concentration-response curve of 2-MeSADP in a parallel manner to the right. For PPADS, a pA(2) value of 5.2 was estimated. The shifts caused by MRS 2210, NF023, and Reactive blue 2 corresponded to apparent pK(B) values of 5.6, 5.0, and 5.8, respectively. In K280A mutant receptors, the affinities of PPADS, MRS 2210, NF023, and Reactive blue 2 were about 6- to 60-fold lower than those observed at wild type receptors. The K280A mutation also caused an approximately 1,000-fold increase in the EC50 value of the agonist 2-MeSADP, similar to previous observations. In contrast, no major change in antagonistic potency was observed at receptors with other mutations in TMs 3, 5, 6, and 7. Thus, the residue Lys(280) (6.55), which is located within the upper third of TM 6 of the human P2Y(1) receptor, is not only critical for the activation of the receptor but also plays-an important role in the binding of pyridoxal derivatives and a number of other chemically unrelated P2 receptor antagonists. Lys(280) seems to belong to an overlapping region of the respective binding sites. Published 2003 Wiley-Liss, Inc.(dagger)
引用
收藏
页码:173 / 181
页数:9
相关论文
共 32 条
  • [1] SOME QUANTITATIVE USES OF DRUG ANTAGONISTS
    ARUNLAKSHANA, O
    SCHILD, HO
    [J]. BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, 1959, 14 (01): : 48 - 58
  • [2] DIFFERENTIAL-EFFECTS OF P-2-PURINOCEPTOR ANTAGONISTS ON PHOSPHOLIPASE C-COUPLED AND ADENYLYL CYCLASE-COUPLED P-2Y-PURINOCEPTORS
    BOYER, JL
    ZOHN, IE
    JACOBSON, KA
    HARDEN, TK
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1994, 113 (02) : 614 - 620
  • [3] P-2-purinoceptor antagonists .3. Blockade of P-2-purinoceptor subtypes and ecto-nucleotidases by compounds related to suramin
    Bultmann, R
    Wittenburg, H
    Pause, B
    Kurz, G
    Nickel, P
    Starke, K
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1996, 354 (04) : 498 - 504
  • [4] Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y1 receptors
    Camaioni, E
    Boyer, JL
    Mohanram, A
    Harden, TK
    Jacobson, KA
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (02) : 183 - 190
  • [5] PPADS and suramin as antagonists at cloned P-2Y- and P-2U-purinoceptors
    Charlton, SJ
    Brown, CA
    Weisman, GA
    Turner, JT
    Erb, L
    Boarder, MR
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (03) : 704 - 710
  • [6] Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924
  • [7] SITE-DIRECTED MUTAGENESIS OF P-2U PURINOCEPTORS - POSITIVELY CHARGED AMINO-ACIDS IN TRANSMEMBRANE HELIX-6 AND HELIX-7 AFFECT AGONIST POTENCY AND SPECIFICITY
    ERB, L
    GARRAD, R
    WANG, YJ
    QUINN, T
    TURNER, JT
    WEISMAN, GA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (09) : 4185 - 4188
  • [8] Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice
    Fabre, JE
    Nguyen, MT
    Latour, A
    Keifer, JA
    Audoly, LP
    Coffman, TM
    Koller, BH
    [J]. NATURE MEDICINE, 1999, 5 (10) : 1199 - 1202
  • [9] FREDHOLM BB, 1994, PHARMACOL REV, V46, P143
  • [10] Furchgott R.F., 1972, Catecholamines, P283